UCB Biopharma SRL clinical trials

A subsidiary of UCB S.A.

The registry lists 129 studies whose lead sponsor is UCB Biopharma SRL. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 129. List all 129 → · All UCB S.A. studies →

• An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisRecruitingNCT06668181Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruitingNCT06617325Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling by invitationNCT04976322Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07463521Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisRecruitingNCT07725939Phase 2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07465289Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisEnrolling by invitationNCT06435312Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisRecruitingNCT06055959Phase 2/3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresRecruitingNCT05077904Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresEnrolling by invitationNCT05076617Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)RecruitingNCT06888193Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRecruitingNCT07246564Phase 4

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis BronchiectasisRecruitingNCT07720375Phase 2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating WomenRecruitingNCT06961747Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisRecruitingNCT07219420Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• SLC6A1-NDD Prospective Longitudinal Natural History StudyRecruitingNCT07531511

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresRecruitingNCT04715646Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsRecruitingNCT07290036Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingNCT06540144Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedNCT06149559Phase 2/3

  Sponsor listed in the registry: UCB Biopharma SRL

• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04225871Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active, not recruitingNCT05063162Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04901195Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.CompletedNCT07849894Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With OsteoporosisCompletedNCT05067335Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03895203Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial SpondyloarthritisCompletedNCT03928704Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT03896581Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242446Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing SpondylitisCompletedNCT03928743Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04242498Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06921850Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisActive, not recruitingNCT07277660Phase 2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06425549Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy ParticipantsTerminatedNCT06555601Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisCompletedNCT04436640Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT04009499Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedNCT06624228Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyActive, not recruitingNCT06315322Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT04124965Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedNCT03971422Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisCompletedNCT04650854Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyCompletedNCT04666610Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT04123795Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04718896Phase 2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyActive, not recruitingNCT04658199Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)CompletedNCT04867616Phase 2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study ParticipantsActive, not recruitingNCT07286682Phase 1

  Sponsor listed in the registry: UCB Biopharma SRL

• A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)CompletedNCT05277571Phase 1/2

  Sponsor listed in the registry: UCB Biopharma SRL

• A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06506916Phase 3

  Sponsor listed in the registry: UCB Biopharma SRL